Cor pulmonale in cystic fibrosis

Seminars in Respiratory and Critical Care Medicine

Volumn 24, Issue 3, 2003, Pages 323-330

  Eckles, Michael ^a   Anderson, Paula ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cor pulmonale; Cystic fibrosis; Oxygen therapy; Pulmonary hypertension

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; DIGOXIN; DIURETIC AGENT; DORNASE ALFA; IBUPROFEN; OXYGEN; THEOPHYLLINE; TOBRAMYCIN; VASODILATOR AGENT;

ANTIBIOTIC THERAPY; AUTOSOMAL RECESSIVE DISORDER; CARDIOTOXICITY; CHLORIDE TRANSPORT; CHRONIC DISEASE; COR PULMONALE; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EPITHELIUM CELL; HUMAN; HYPOKALEMIA; HYPOXEMIA; INTRACELLULAR TRANSPORT; LUNG ARTERY PRESSURE; LUNG CLEARANCE; LUNG INFECTION; LUNG INSUFFICIENCY; LUNG TRANSPLANTATION; METABOLIC ALKALOSIS; OXYGEN THERAPY; OXYGENATION; PANCREAS INSUFFICIENCY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECURRENT INFECTION; REVIEW; SURVIVAL; SWEATING;

EID: 0038336888     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41093     Document Type: Review

References (54)

1. Kosork MR, Wei WH, Farrell PM. The incidence of cystic fibrosis. Stat Med 1996;15:449-462
2. Cystic Fibrosis Foundation. Patient Registry 2000 Annual Report. Bethesda, MD: Cystic Fibrosis Foundation; 2001
3. Yankaskas JR, Knowles MR. Cystic Fibrosis in Adults. Philadelphia: Lippincott-Raven; 1999:45-67
4. Cystic Fibrosis Foundation. Clinical Practice Guidelines for Cystic Fibrosis. Washington, DC: Cystic Fibrosis Foundation; 1997
5. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073
6. Kerem E, Corey M, Kerem BS, et al. The relationship between genotype and phenotype in cystic fibrosis: analysis of the most common mutation (ΔF508). N Engl J Med 1990; 323:1517-1522
7. Stern RC. The diagnosis of cystic fibrosis. N Engl J Med 1997;336:487-491
8. Welsh MJ, Anderson MP, Rich DP, et al. Cystic fibrosis, CFTR, and abnormal electrolyte transport. In: Davis PB, ed. Cystic Fibrosis. New York: Marcel Dekker; 1993:29-52
9. Cutting GR. Genotype defect: its effect on cellular function and phenotypic expression. Sem Respir Crit Care Med 1994; 15:356
10. Seeger W, Suttorp N. Role of membrane lipids in the pulmonary vascular abnormalities caused by bacterial toxins. Am Rev Respir Dis 1987;136:462-466
11. Stern R. Inpatient treatment of cystic fibrosis pulmonary disease. In: Orenstein DM, Stern RC, eds. Treatment of the Hospitalized Cystic Fibrosis Patient. New York: Marcell Dekker; 1998:79-133
12. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-188
13. Royce SW. Cor pulmonale in infancy and early childhood: report on 34 patients, with special reference to the occurrence of pulmonary heart disease in cystic fibrosis of the pancreas. Pediatrics 1951;8:255-274
14. Stern RC, Borkat G, Hirschfeld SS, et al. Heart failure in cystic fibrosis: treatment and prognosis of cor pulmonale with failure of the right side of the heart. Am J Dis Child 1980; 134:267-272
15. Levesque PC, Padraig JH, Hume JR, Kenyon JL, Horowitz B. Expression of cystic fibrosis transmembrane regulator Cl-channels in heart. Circ Res 1992;711:1002-1007
16. Hart P, Warth JD, Leresque PC, et al. Cystic fibrosis gene encodes a cAMP-dependent chloride channel in heart. Proceedings of the National Academy of Sciences of the United States of America. 1996;93:6343-6348
17. Goldring RM, Fishman AP, Turino GM, Cohen HI, Denning CR, Andersen DH. Pulmonary hypertension and cor pulmonale in cystic fibrosis of the pancreas. J Pediatrics 1964; 65:501-524
18. Symchych PS. Pulmonary hypertension in cystic fibrosis. Arch Pathol 1971;91:409-414
19. Fraser KL, Tullis DE, Sasson Z, Hyland RH, Thornley KS, Hanly PJ. Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Chest 1999;115:1321-1328
20. 2 on the pulmonary vascular bed of the cat. Am J Physiol 1968;215:1170-1176
21. Enson Y, Giuntini C, Lewis ML, et al. The influence of hydrogen ion concentration and hypoxia on the pulmonary circulation. J Clin Invest 1964;43:1146
22. Jessup M, Sutton SG, Weber K, et al. The effect of chronic pulmonary hypertension on left ventricular size, function, and interventricular septal motion. Am Heart J 1987;113:1114-1122
23. Jacobstein MD, Hirschfeld SS, Winnie G, Doershuk C, Liebman J. Ventricular interdependence in severe cystic fibrosis. Chest 1981;80:399-404
24. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998;113:576-583
25. Hortop J, Desmond KJ, Coates AL. The mechanical effects of expiratory airflow limitation on cardiac performance in cystic fibrosis. Am Rev Respir Dis 1988;137:132-137
26. Moss AJ. The cardiovascular system in cystic fibrosis. Pediatrics 1982;70:728-741
27. Fowler RS, Rappaport H, Cunningham K, Crozier DN, Levison H, Rowe RD. Cor pulmonale in cystic fibrosis. J Electrocardiology 1981;14:319-324
28. Gewitz M, Eshaghpour E, Holsclaw DS, et.al. Echocardiography in cystic fibrosis. Am J Dis Child 1977;131:275-280
29. Ionescu AA, Ionescu A, Payne N, Obieta-Fresnedo I, Fraser AG, Shale DJ. Subclinical right ventricular dysfunction in cystic fibrosis. Am J Respir Crit Care Med 2001;163:1212-1218
30. Rosenthal A, Tucker CR, Williams RG, Khaw KT, Strieder D, Schwachman H. Echocardiographic assessment of cor pulmonale in cystic fibrosis. Pediatr Clin North Am 1976;23:327-344
31. Ryssing E. Assessment of cor pulmonale in cystic fibrosis by echocardiography. Acta Pediatr Scand 1977;66:753-756
32. Panidis IP, Ren JF, Holsclaw DS, Kotler MN, Mintz GS, Ross J. Cardiac function in patients with cystic fibrosis: evaluation by two-dimensional and Doppler echocardiography. J Am Coll Cardiol 1985;6:701-706
33. Piepsz A, Ham HR, Millet E, Dab I. Determination of right ventricular ejection fraction in children with cystic fibrosis. Pediatr Pulmonol 1987;3:24-28
34. Florea VG, Florea ND, Sharma R, et al. Right ventricular dysfunction in adult severe cystic fibrosis. Chest 2000;118:1063-1068
35. Ramsey BW, Pepe MS, Quan JN, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30
36. Fuchs JF, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642
37. Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-854
38. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-398
39. Bradley TD, Rutherford R, Gorssman RF, et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 1985;131:835-839
40. Stokes DC, McBride JT, Wall MA, Erba G, Strieder DJ. Sleep hypoxemia in young adults with cystic fibrosis. Am J Dis Child 1980;134:741-743
41. Coffey MJ, FitzGerald MX, McNicholas WT. Comparison of oxygen desaturation during sleep and exercise in patients with cystic fibrosis. Chest 1991;100:659-662
42. Tepper RS, Skatrud JB, Dempsey JA. Ventilation and oxygenation changes during sleep in cystic fibrosis. Chest 1983; 84:388-393
43. Becker HF, Piper AJ, Flynn WE, et al. Breathing during sleep in patients with nocturnal desaturation. Am J Respir Crit Care Med 1999;159:112-118
44. Frangolis DD, Despina D, Wilcox PG. Predictability of oxygen desaturation during sleep in patients with cystic fibrosis: clinical, spirometric, and exercise parameters. Chest 2001; 119:434-441
45. Villa MP, Pagani J, Lucidi V, Plamides S, Ronchetti R. Nocturnal oximetry in infants with cystic fibrosis. Arch Dis Child 2001;84:50-54
46. Nixon PA, Orenstein DM, Curtis SE, Ross EA. Oxygen supplementation during exercise in cystic fibrosis. Am Rev Respir Dis 1990;142:807-811
47. Versteegh FGA, Borgarrd JM, Raatgever JW, Stam H, Neijens JF, Kerrebijn KF. Relationship between airway obstruction, desaturation during exercise and nocturnal hypoxaemia in cystic fibrosis patients. Eur Respir J 1990;3:68-73
48. Nixon P, Orenstein D, Kelsey S, Doershuk C. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 1992;327:1785-1788
49. Zinman R, Corey M, Coates AL, et al. Nocturnal home oxygen in the treatment of hypoxemic cystic fibrosis patients. J Ped 1989;114:368-377
50. Dinwiddle R, Madge S, Prasad SA, Balfour-Lynn IM. Oxygen therapy for cystic fibrosis. J R Soc Med 1999;92(suppl 37):S19-S22
51. Geggel RL, Dozor AJ, Flyler DC, Reid LM. Effect of vasodilators at rest and during exercise in young adults with cystic fibrosis and chronic cor pulmonale. Am Rev Respir Dis 1985;131:531-536
52. Michael JR, Kennedy TP, Fitzpatrick S, Rosenstein BJ. Nifedipine inhibits hypoxic pulmonary vasoconstriction during rest and exercise in patients with cystic fibrosis and cor pulmonale. Am Rev Respir Dis 1984;130:516-519
53. Yankaskas JR, Mallory GB. Lung transplantation in cystic fibrosis: consensus conference statement. Chest 1998;113:217-226
54. Yacoub MH, Banner NR, Khaghani A, et al. Heart-lung transplantation for cystic fibrosis and subsequent domino heart transplantation. J Heart Transplant 1990;9:459